An interventional study of PVI-ONLY, CONTROL ARM and PVI-PLUS ARM, INTERVENTIONAL ARM in Atrial Fibrillation, Catheter Ablation and Radiofrequency Catheter Ablation, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation — 7 open to participants now, 11 under way, none of them phase 3. Atrial Fibrillation · Ottawa Heart Institute Research Corporation.
Among the 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 19th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →7 of the 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation are open now, in 2 countries. Recruiting first, the newest first:
Ottawa Heart Institute Research Corporation · Sites in United States, Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 40+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 556 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 102 across the 21 interventional studies, 321 across the 3 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.
3 of the studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02150902Ottawa Heart Institute Research CorporationAugmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence | 2026-11-27 |
| NCT05136131Ottawa Heart Institute Research CorporationQOL Improvement After Cardioversion of Persistent AF (QOL-CAFRCT) | 2027-05 |
| NCT06556667Ottawa Heart Institute Research CorporationMAX - SHOCK Clinical Trial | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effective than medications for controlling symptoms and reducing the risk of these complications; however, recurrence of AF after ablation remains a significant challenge, often due to incomplete or ineffective initial procedures. This clinical trial aims to determine whether a novel, patient-tailored ablation strategy can improve outcomes compared to the current standard-of-care approach. Participants will be randomly assigned to undergo either standard pulmonary vein isolation or a more individualized ablation procedure that identifies and targets patient-specific sources of AF. All participants will undergo the ablation procedure, receive continuous heart rhythm monitoring, and be followed over time to assess recurrence and safety outcomes.
This study is a randomized controlled trial evaluating two different catheter ablation strategies for patients with paroxysmal atrial fibrillation (AF). Participants are randomly assigned in a 1:1 ratio to either the control arm or the experimental arm prior to undergoing their ablation procedure. In the control arm, patients receive a pulmonary vein isolation (PVI)-only strategy using pulsed field ablation (PFA). This approach targets only the pulmonary veins, which are the most common source of AF triggers, and does not include additional ablation beyond isolating these veins. In contrast, the experimental arm uses a more comprehensive PVI-PLUS strategy with radiofrequency ablation (RFA). In addition to standard pulmonary vein isolation, this strategy includes patient-specific ablation of non-pulmonary vein triggers and abnormal atrial substrate, such as low-voltage areas identified during electrophysiologic testing. This individualized approach aims to reduce arrhythmia recurrence by addressing additional sources of AF beyond the pulmonary veins.
All participants undergo their assigned catheter ablation procedure as part of routine clinical care, with procedural details tailored according to the randomized strategy. Following the ablation, patients receive an implantable loop recorder (ILR), which is a small device placed under the skin that continuously monitors heart rhythm. The ILR allows for continuous, long-term detection of atrial arrhythmias, including both symptomatic and asymptomatic episodes, ensuring accurate assessment of treatment outcomes throughout the study period.
Participants are followed closely for a total of 24 months after the ablation procedure. During this follow-up period, patients attend scheduled visits at 2, 6, 12, 18, and 24 months, where ILR data are reviewed and clinical assessments are performed. The continuous monitoring provided by the ILR is central to evaluating the study's primary and secondary outcomes, including recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia. In addition to rhythm monitoring, patients complete quality-of-life questionnaires at baseline and at 24 months, and any repeat procedures, hospital visits, or complications are recorded. This structured follow-up ensures comprehensive evaluation of both the effectiveness and safety of the two ablation strategies over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must have paroxysmal AF with at least one episode of AF over the past 12 months (patients on antiarrhythmic medications do not need to satisfy this criterion).
At least one episode of AF documented on 12-lead , Holter monitor, Trans-telephonic monitor (TTM) or Loop Recorder.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulsed Field Ablation (PFA), control arm
Procedure: PVI-ONLY, CONTROL ARM
RADIOFREQUENCY CATHETER ABLATION (RFA), interventional arm
Procedure: PVI-PLUS ARM, INTERVENTIONAL ARM
PULSED FIELD ABLATION (PFA) PVI-ONLY STRATEGY: CONTROL ARM
RADIOFREQUENCY CATHETER ABLATION (RFA) PVI-PLUS : INTERVENTION ARM
Freedom from atrial fibrillation, atrial flutter or atrial tachycardia
AF, AFl or AT, symptomatic or asymptomatic lasting ≥ 30 seconds
Time frame: 61 to 730 days after ablation
Atrial fibrillation burden
Total duration of AF recorded on ambulatory monitoring/total duration of monitoring
Time frame: 730 days
Long-term rate of documented atrial fibrillation, atrial flutter or atrial tachycardia
Long-term rate of documented AF, AFl or AT lasting ≥ 30 seconds
Time frame: 730 days
Incidence of any ECG/ILR documented atrial fibrillation, atrial flutter or atrial tachycardia
Incidence of any ECG/ILR documented AF, AFl or AT (symptomatic or asymptomatic; lasting ≥ 30 seconds
Time frame: First 60 days after catheter ablation
Ablation procedure duration
Catheter ablation procedure time
Time frame: On day of ablation
Fluoroscopic exposure
Fluoro time in minutes
Time frame: On day of ablation
Composite Safety outcomes
Procedure Related Complications at any time including Stroke, PV stenosis, pericarditis, phrenic nerve palsy, cardiac perforation, atrio-esophageal fistula, major bleeding and/or death.
Time frame: 730 days
Emergency room visits or hospitalization due to recurrent atrial fibrillation, atrial flutter or atrial tachycardia
Emergency room visits or hospitalization due to recurrent atrial fibrillation, atrial flutter or atrial tachycardia
Time frame: 730 days
Repeat catheter ablation for atrial fibrillation, atrial flutter or atrial tachycardia
Repeat catheter ablation for atrial fibrillation, atrial flutter or atrial tachycardia
Time frame: 730 days
Quality of life scale
EuroQol 5-Dimension questionnaire (EQ-5D), scale of 0-100, higher is better perceived health.
Time frame: 12 and 24 months
Health Economic analyses
Health Economic analyses
Time frame: 730 days
Cumulative duration of Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia (atrial burden)
Cumulative duration of AF, AFL or AT (atrial burden) from day 61 after interventions to end of follow-up
Time frame: Day 61- Day 730
Comparison of primary outcome events between patients undergoing PVI-ONLY and PVI-PLUS
Comparison of primary outcome events (freedom from atrial fibrillation, atrial flutter or atrial tachycardia) between patients undergoing PVI only (due to lack of additional triggers/substrate) in the PVI-PLUS strategy and those in the PVI-ONLY group.
Time frame: 730 days
Fluoroscopic exposure
Total Air Kerma
Time frame: On day of ablation
Fluoroscopic exposure
Dose Area Protocol.
Time frame: On day of ablation
Quality of life scale
Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT), 0-100 score range, 100 - no impairment, and 0-very poor quality of life.
Time frame: 12 and 24 months
Quality of life scale
Canadian Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF), score range 0-4, higher score being worse symptoms, or greater impairment.
Time frame: 12 and 24 months
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Heart Institute Research Corporation →